[go: up one dir, main page]

PE20030808A1 - Derivados triciclicos heterociclicos como antagonistas receptores de trombina - Google Patents

Derivados triciclicos heterociclicos como antagonistas receptores de trombina

Info

Publication number
PE20030808A1
PE20030808A1 PE2002001022A PE2002001022A PE20030808A1 PE 20030808 A1 PE20030808 A1 PE 20030808A1 PE 2002001022 A PE2002001022 A PE 2002001022A PE 2002001022 A PE2002001022 A PE 2002001022A PE 20030808 A1 PE20030808 A1 PE 20030808A1
Authority
PE
Peru
Prior art keywords
alkyl
alcoxy
heterocyclic
receptor antagonists
thrombin receptor
Prior art date
Application number
PE2002001022A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Yan Xia
Martin C Clasby
Mariappan V Chelliah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030808A1 publication Critical patent/PE20030808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A DERIVADOS TRICICLICOS HETEROCICLICOS DE FORMULA I DONDE R ES H, ALQUILO C1-C5, HALOGENO, HIDROXI, AMINO, (C1-C6) ALQUILO-AMINO, (C1-C6)-DIALQUILAMINO, ALCOXI C1-C6, ENTRE OTROS; R1 Y R2 SON H, ALQUILO C1-C6, FLUOR(C1-C6)ALQUILO, DIFLUOR(C1-C6)ALQUILO, CICLOALQUILO C3-C6, ENTRE OTROS; R3 ES H, OH, ALCOXI C1-C6, ARILOXI, ARIL(C1-C6)ALQUILOXI, HETEROARILOXI, HETEROARIL(C1-C6)ALQUILOXI, ENTRE OTROS; n ES 1-4; n1 Y n2 SON 0-3; Het ES UN GRUPO HETEROAROMATICO MONO-BI, TRICICLICO DE 5 A 14 ATOMOS DE CARBONO; R4 Y R5 SON H, ALQUILO C1-C6, FENILO, BENCILO, CICLOALQUILO C3-C6; R4 Y R5 JUNTO A (CH2)3, (CH2)4 FORMAN UN ANILLO CON EL NITROGENO AL CUAL ESTAN ADHERIDOS; R7 ES H, ALQUILO C1-C6; R8, R10 Y R11 SON R1 Y -OR1; R9 ES H, OH, -NR4R5, ALCOXI C1-C6, HALOGENO, HALO (C1-C6)ALQUILO; B ES -(CH2)n3, ENTRE OTROS; R22 ES -COR23, ENTRE OTROS; R23 ES HALO(C1-C6)ALQUILO, ALQUENILO C2-C6, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS DE FORMULA I SON ANTAGONISTAS DE RECEPTORES DE TROMBINA Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A TROMBOSIS, ATEROESCLEROSIS, RESTENOSIS, HIPERTENSION
PE2002001022A 2001-10-18 2002-10-16 Derivados triciclicos heterociclicos como antagonistas receptores de trombina PE20030808A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33035901P 2001-10-18 2001-10-18

Publications (1)

Publication Number Publication Date
PE20030808A1 true PE20030808A1 (es) 2003-09-22

Family

ID=23289411

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001022A PE20030808A1 (es) 2001-10-18 2002-10-16 Derivados triciclicos heterociclicos como antagonistas receptores de trombina

Country Status (23)

Country Link
US (2) US7037920B2 (es)
EP (1) EP1436298B1 (es)
JP (2) JP4307260B2 (es)
KR (1) KR100960170B1 (es)
CN (1) CN100369917C (es)
AR (1) AR036832A1 (es)
AT (1) ATE525378T1 (es)
AU (1) AU2002335031C1 (es)
BR (1) BR0213967A (es)
CA (1) CA2463628A1 (es)
CO (1) CO5570668A2 (es)
EC (1) ECSP045064A (es)
HU (1) HUP0500443A3 (es)
IL (1) IL160918A0 (es)
MX (1) MXPA04003610A (es)
MY (1) MY139335A (es)
NO (1) NO329349B1 (es)
NZ (1) NZ531869A (es)
PE (1) PE20030808A1 (es)
PL (1) PL371948A1 (es)
RU (1) RU2319704C9 (es)
WO (1) WO2003033501A1 (es)
ZA (1) ZA200402849B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
DE60317493T3 (de) 2002-04-16 2018-07-12 Merck Sharp & Dohme Corp. Trizyklische thrombin rezeptor antagonisten
US20070243632A1 (en) * 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
ES2378544T3 (es) * 2003-07-08 2012-04-13 Accumetrics, Inc. Activación selectiva de plaquetas para el seguimiento de terapia con antagonistas de ADP
EP1751144B1 (en) * 2004-05-28 2008-08-27 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
RU2408594C2 (ru) * 2004-10-08 2011-01-10 Шеринг Корпорейшн Антагонисты рецептора тромбина
CA2594741A1 (en) * 2005-01-14 2006-07-20 Schering Corporation Synthesis of himbacine analogs
CN102757423B (zh) 2005-01-14 2016-04-20 先灵公司 喜巴辛类似物的外型和非对映立体选择合成
JP4775971B2 (ja) * 2005-01-14 2011-09-21 シェーリング コーポレイション ヒンバシンアナログのエキソ−選択的合成
US7776889B2 (en) * 2005-03-31 2010-08-17 Schering Corporation Spirocyclic thrombin receptor antagonists
US7595169B2 (en) * 2005-04-27 2009-09-29 Accumetrics, Inc. Method for determining percent platelet aggregation
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
JP2009521458A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
AR060095A1 (es) 2006-03-29 2008-05-21 Schering Corp Derivados de himbacina monociclicos y biciclicos utiles como antogonistas de los receptores de trombina
WO2007120730A2 (en) * 2006-04-13 2007-10-25 Schering Corporation Fused ring thrombin receptor antagonists
AU2007269830A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2069326B1 (en) * 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
MX2009003758A (es) * 2006-10-04 2009-04-22 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
ES2387700T3 (es) * 2007-05-03 2012-09-28 Accumetrics, Inc. Métodos para medir la inhibición de la agregación de plaquetas mediante antagonistas del receptor de trombina
AU2009211887B2 (en) 2008-02-05 2013-09-19 Sanofi Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
CA2724430A1 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
PT2438060E (pt) 2009-06-04 2013-12-16 Merck Sharp & Dohme Metabolito ativo de um antagonista do recetor da trombina
CA2764172A1 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
CN104610330A (zh) * 2015-02-25 2015-05-13 成都安斯利生物医药有限公司 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法
WO2022018156A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
JP2000229961A (ja) * 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
WO1999026943A1 (en) * 1997-11-25 1999-06-03 Schering Corporation Thrombin receptor antagonists
DE19801636A1 (de) * 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
EP1294714B1 (en) 2000-06-15 2007-08-01 Schering Corporation Thrombin receptor antagonists

Also Published As

Publication number Publication date
HUP0500443A2 (hu) 2005-08-29
CN1571789A (zh) 2005-01-26
NO20042021L (no) 2004-05-14
HUP0500443A3 (en) 2009-12-28
RU2319704C9 (ru) 2008-08-20
AU2002335031B2 (en) 2005-06-30
EP1436298A1 (en) 2004-07-14
CN100369917C (zh) 2008-02-20
WO2003033501A1 (en) 2003-04-24
CA2463628A1 (en) 2003-04-24
EP1436298B1 (en) 2011-09-21
PL371948A1 (en) 2005-07-11
JP2009029820A (ja) 2009-02-12
MY139335A (en) 2009-09-30
RU2319704C2 (ru) 2008-03-20
KR20050036845A (ko) 2005-04-20
JP4307260B2 (ja) 2009-08-05
NZ531869A (en) 2006-11-30
JP2005529841A (ja) 2005-10-06
ECSP045064A (es) 2004-05-28
MXPA04003610A (es) 2004-07-27
CO5570668A2 (es) 2005-10-31
KR100960170B1 (ko) 2010-05-26
RU2004115114A (ru) 2005-10-27
NO329349B1 (no) 2010-10-04
IL160918A0 (en) 2004-08-31
US20030203927A1 (en) 2003-10-30
AU2002335031C1 (en) 2006-11-16
US20060106050A1 (en) 2006-05-18
US7037920B2 (en) 2006-05-02
BR0213967A (pt) 2005-08-30
ATE525378T1 (de) 2011-10-15
AR036832A1 (es) 2004-10-06
ZA200402849B (en) 2005-01-14

Similar Documents

Publication Publication Date Title
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20040832A1 (es) Derivados de indolil pirazinona
MY144040A (en) Tricyclic thrombin receptor antagonists
PE20020366A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE54294A1 (es) Derivado de 5-aminoalquil-1,4-benzodiazepina
PE20071064A1 (es) Derivados de pirrolonaftiridinonas como antibacterianos
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR047063A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide
CO5640091A2 (es) Antagonista de un receptor sensible al calcio
CO5721000A2 (es) (tiazol-2-il)-amida o sulfonamida substituida como activado- res de glicocinasa utiles en el tratamiento de diabetes de tipo 2
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR049652A1 (es) Sales cuaternarias antagonistas del receptor ccr2
PE20010522A1 (es) Aminoalcoxicarbazoles como antagonistas de los receptores 5ht
PE20220904A1 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
PE133799A1 (es) Antagonistas del receptor de trombina
PE20200664A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20000011A1 (es) Combinacion eficaz para el tratamiento de la impotencia
CO5590924A2 (es) Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR045805A1 (es) Quinolonas y naftridonas 7- amino alquidenil - heterociclicas
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed